Scarica l'app Stockscreener
5.41
1.28%
-0.07
Dopo l'orario di chiusura:
5.42
0.010
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - MSN
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - Yahoo Finance
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest
Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest
Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest
Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga
Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com
Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com
Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest
Why Recursion Pharmaceuticals Shares Are Gaining Momentum - TipRanks
Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Reports Q2 Financial Results, Deploys Advanced Models for Medicine Discovery. - AInvest
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN
Recursion Pharmaceuticals Earnings Preview - 富途牛牛
Recursion Pharmaceuticals Q2 2025 Earnings: A TechBio Inflection Point? - AInvest
Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals - AInvest
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Maximize portfolio growth with professional advice - Jammu Links News
Why is Recursion Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - Jammu Links News
How does Recursion Pharmaceuticals Inc. generate profit in a changing economyFree Predictions - Jammu Links News
Does Recursion Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on emerging investment opportunities - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
What makes Recursion Pharmaceuticals Inc. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockDiscover hidden gems in the stock market - Jammu Links News
When is Recursion Pharmaceuticals Inc. stock expected to show significant growthExplosive earning power - Jammu Links News
What institutional investors are buying Recursion Pharmaceuticals Inc. stockHigh-octane gains - Jammu Links News
Should I hold or sell Recursion Pharmaceuticals Inc. stock in 2025Outstanding growth strategies - Jammu Links News
0.71%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):